10x Genomics shares are trading lower after the company guided Q3 preliminary revenue of ~$151.7 million, down 1% year over year.
Portfolio Pulse from Benzinga Newsdesk
10x Genomics shares fell as the company announced a preliminary Q3 revenue of approximately $151.7 million, marking a 1% decline year over year.
October 09, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
10x Genomics reported a preliminary Q3 revenue of ~$151.7 million, representing a 1% decrease compared to the previous year, leading to a drop in share prices.
The announcement of a year-over-year revenue decline is a negative indicator for investors, likely causing a decrease in stock price as it suggests potential challenges in the company's growth or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100